NCI awards five-year, $13.3M grant for collaborative study on sequential combinations of targeted inhibitors, immunotherapies

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

President-elect Donald Trump said he would nominate Robert F. Kennedy Jr. to the post of secretary of the Department of Health and Human Services, placing the vaccine skeptic in charge of a vast empire of research, engineering, regulatory, and health care agencies.

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

The University of Texas MD Anderson Cancer Center launched its Institute for Cell Therapy Discovery & Innovation.

November 15, 2024

Vol.50 No.43

In Brief

NCI renews IU Simon Comprehensive Cancer Center’s designation

NCI renewed the Comprehensive Cancer Center designation to the Indiana University Melvin and Bren Simon Comprehensive Cancer Center, awarding it a five-year, $14.2 million grant.

November 15, 2024

Vol.50 No.43

Clinical Roundup

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

November 15, 2024

Vol.50 No.43

Clinical Roundup

USC study identifies innate immune system protein as potential target for CRC immunotherapy

Researchers from the USC Norris Comprehensive Cancer Center found evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases. The study has found evidence that targeting CD47, a protein that is part of the innate immune system, could be a key step in fighting colorectal cancer.

November 15, 2024

Vol.50 No.43

Clinical

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.

October 25, 2024

Vol.50 No.40

By Claire Marie Porter

NCI awards five-year, $13.3M grant for collaborative study on sequential combinations of targeted inhibitors, immunotherapies

YOU MAY BE INTERESTED IN

As Trump’s HHS pick, RFK Jr. stands to honor or squander the Kennedy legacy in cancer

MD Anderson launches Institute for Cell Therapy Discovery & Innovation

NCI renews IU Simon Comprehensive Cancer Center’s designation

Combination immunotherapy + chemo is safe and effective for advanced small cell cancers in bladder and prostate

USC study identifies innate immune system protein as potential target for CRC immunotherapy

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials

Renew today!

Subscriber content

Never miss an issue!

Login